Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Location: United States, Connecticut, New Haven
Employees: 201-500
Total raised: $114.85M
Founded date: 2013
Investors 6
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| - | 5AM Ventur... | 5amventure... |
| - | RA Capital... | racap.com |
| - | Canaan Par... | canaan.com |
| - | Solasta Ve... | solasta-ve... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 04.04.2018 | Series C | $55M | - |
| 21.10.2015 | Series B | $41.6M | - |
| 26.09.2013 | - | $18.25M | - |
Mentions in press and media 17
| Date | Title | Description | Source |
| 09.04.2018 | The biotech, digital health VC to know | Julie Papanek Grant, a partner at Silicon Valley healthcare and tech VC firm Canaan Partners, has ma... | medcitynew... |
| 05.04.2018 | Term Sheet — Thursday April 5 | GOT MONEY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? Fro... | fortune.co... |
| 04.04.2018 | Arvinas Completes $55 Million Series C Financing | Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradat... | citybizlis... |
| 04.04.2018 | Arvinas Completes $55M Series C Financing | Arvinas, LLC, a New Haven, Conn.-based biotechnology company creating a new class of drugs based on ... | finsmes.co... |
| 04.04.2018 | Arvinas Completes $55 Million Series C Financing to Advance ... | - | 5amventure... |
| 04.04.2018 | Arvinas gains $55M C round as it eyes cancer trials, pipelin... | Former Fierce 15 winner Arvinas, which has caught the attention of Pfizer and Roche over the last ye... | fiercebiot... |
| 04.04.2018 | Arvinas Completes $55M Series C | NEW HAVEN, CT, Biotechnology company creating a new class of drugs based on protein degradation, t... | vcnewsdail... |
| 04.01.2018 | Pfizer and Arvinas sign $830M drug development deal that tar... | So what’s attracting the big fish? There are no clinical programs tied up in any of the deals. Inste... | medcitynew... |
| 21.10.2015 | Arvinas Secures $41.6M Series B | NEW HAVEN, CT, Private biotechnology company has closed a Series B financing round of $41.6 millio... | vcnewsdail... |
| 21.10.2015 | Arvinas Closes $41.6M Series B Financing Round | Arvinas LLC, a New Haven, CT-based private biotechnology company creating a new class of drugs based... | finsmes.co... |
Show more